OBJECTIVES: To estimate the percentage of annual follow up medication cost attributed to each kind of treatment of unselected patients subjected to CRMDs implantation in a real-world setting. METHODS: During a period of one year in total 464 (370 were subjected to PM implantation, 240 initial, 130 replacement and 94 to ICD implantation, 80 initial, 14 replacement) consecutive recipients were subjected to CRMD’s implantation and furthermore were recruited and followed up for 1 year. At six and twelve months after the procedure of implantation we record the medication use for each patient. RESULTS: For the patients were subjected in PM initial implantation antiplatelet–anticoagulants represent 24,5%, antiarrhythmic 1,1,%, cardiovascular 47,8%, lipid–lowering 22,6% and antidiabetics 3,9% of the total annual follow up medication cost. For the patients were subjected to PM replacement antiplatelet–anticoagulants represent 19,6%%, antiarrhythmic 1,7%, cardiovascular 49,9%, lipid–lowering 22,7% and Antidiabetics the 6,1% of the total annual follow up medication cost . For the patients were subjected to ICD initial implantation antiplatelet–anticoagulants represent 24,4 %, antiarrhythmic 2,2 %, cardiovascular 44,2 %, lipid–lowering 25,0% and antidiabetics 4,1% of the total annual follow up medication cost. For the patients were subjected to ICD replacement antiplatelet–anticoagulants represent the 28,7 %, antiarrhythmic the 7,7 %, Cardiovascular 58,1 %, Lipid–lowering 5,5% and Antidiabetics 0,0% of the total annual follow up medication cost . CONCLUSIONS: The present study provides unique data regarding the percentage of annual medication cost attributed to each kind of treatment of unselected patients subjected to CRMDs implantation in a real-world setting.